trending Market Intelligence /marketintelligence/en/news-insights/trending/r_V2ZYpQU4x0Dqb1oGgFJA2 content esgSubNav
In This List

PTC Therapeutics plans $100M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PTC Therapeutics plans $100M common stock offering

PTC Therapeutics Inc. is planning to sell $100 million of its common shares in a public offering.

The South Plainfield, N.J.-based company also plans to grant the underwriter a 30-day option to buy up to an additional $15 million of common shares.

Credit Suisse is sole book-running manager for the offer.

PTC Therapeutics is a biopharmaceutical company developing therapies for rare disorders. The company offers Translarna and Emflaza for treating patients with Duchenne muscular dystrophy.